Standard BioTools Inc. (LAB)
NASDAQ: LAB · Real-Time Price · USD
0.9550
+0.0224 (2.40%)
Mar 16, 2026, 4:00 PM EDT - Market closed
Standard BioTools Revenue
In the year 2025, Standard BioTools had annual revenue of $85.33M, down -51.08%. Standard BioTools had revenue of $23.80M in the quarter ending December 31, 2025, a decrease of -49.07%.
Revenue (ttm)
$105.90M
Revenue Growth
-22.61%
P/S Ratio
4.37
Revenue / Employee
$104,317
Employees
818
Market Cap
372.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 85.33M | -89.10M | -51.08% |
| Dec 31, 2024 | 174.43M | 68.09M | 64.03% |
| Dec 31, 2023 | 106.34M | 8.39M | 8.57% |
| Dec 31, 2022 | 97.95M | -32.63M | -24.99% |
| Dec 31, 2021 | 130.58M | -7.56M | -5.47% |
| Dec 31, 2020 | 138.14M | 20.90M | 17.83% |
| Dec 31, 2019 | 117.24M | 4.28M | 3.79% |
| Dec 31, 2018 | 112.96M | 11.03M | 10.82% |
| Dec 31, 2017 | 101.94M | -2.51M | -2.40% |
| Dec 31, 2016 | 104.45M | -10.27M | -8.95% |
| Dec 31, 2015 | 114.71M | -1.74M | -1.50% |
| Dec 31, 2014 | 116.46M | 45.27M | 63.60% |
| Dec 31, 2013 | 71.18M | 18.85M | 36.02% |
| Dec 31, 2012 | 52.33M | 9.47M | 22.09% |
| Dec 31, 2011 | 42.87M | 9.31M | 27.73% |
| Dec 31, 2010 | 33.56M | 8.15M | 32.06% |
| Dec 31, 2009 | 25.41M | 10.07M | 65.58% |
| Dec 27, 2008 | 15.35M | 8.07M | 110.96% |
| Dec 29, 2007 | 7.28M | 877.00K | 13.71% |
| Dec 31, 2006 | 6.40M | -1.28M | -16.63% |
| Dec 31, 2005 | 7.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Varex Imaging | 854.40M |
| Orthofix Medical | 822.31M |
| Viemed Healthcare | 270.28M |
| OrthoPediatrics | 236.35M |
| Cerus | 206.13M |
| Pacific Biosciences of California | 160.01M |
| RxSight | 134.48M |
| Beta Bionics | 100.25M |
LAB News
- 20 days ago - Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewsWire
- 6 weeks ago - Standard BioTools Completes Sale of SomaLogic to Illumina - GlobeNewsWire
- 2 months ago - Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue - GlobeNewsWire
- 4 months ago - Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry - Business Wire
- 4 months ago - Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks - PRNewsWire
- 4 months ago - Standard BioTools Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025 - GlobeNewsWire